By Business Wire, March 12, 2013, 01:02:00 PM EDT
Initiation of the pivotal registration phase III trial
PARIS--(BUSINESS WIRE)--
Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative
Company dedicated to the development of orphan oncology products and to
supportive care products, announces the initiation of Loramyc®/Oravig®
Phase III clinical trial for the treatment of oropharyngeal
candidiasis by its Japanese partner Sosei. This is the final step before
registration of the drug by Japanese authorities.
In May 2011, BioAlliance Pharma signed a licensing agreement with Sosei
Co. Ltd. (a wholly owned subsidiary of Sosei Group Corporation - TSE
Mothers Index: 4565) for the conduct of development program and
commercialization rights in Japan for Loramyc®/Oravig®
(miconazole Lauriad®) muco-adhesive buccal tablet.
As traditionally required by Japanese authorities, a complementary
development plan driven by Sosei has been initiated to complete the
registration dossier and meet Japanese regulatory requirements.
Following the successful phase I clinical trial finalized in July 2012,
Sosei is now starting the final step of development with the phase III
open-label, randomised trial versus miconazole gel. This study is
anticipated to last 12 to 18 months.
"Loramyc®/Oravig®
represents a true innovation in the treatment of oropharyngeal
candidiasis as compared with available treatments and is expected to
improve patients' compliance and quality of life", commentsShinichi
Tamura, CEO of Sosei Group Corporation. "The initiation of this phase
III trial is a key step for us, not only in the development plan of the
product in Japan but also in our discussions with potential partners for
commercialization once the product is approved".
"We are very pleased with this new step taken by our partner Sosei in
Japan, which should lead them to the final stage of registration in the
coming months. From there, commercialization of Loramyc®
should then start in one of the major Asian markets that is Japan",
adds Judith Greciet, CEO of BioAlliance Pharma.
About BioAlliance Pharma
Dedicated to cancer and supportive
care treatment with a focus on resistance targeting and orphan products,
BioAlliance conceives and develops innovative products, for specialty
markets especially in the hospital setting and for orphan or rare
diseases.
Created in 1997 and introduced to the Euronext Paris
market in 2005, BioAlliance Pharma's ambition is to become a leading
player in these fields by coupling innovation to patient needs. The
company's teams have the key competencies required to identify, develop
and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product portfolio:
Specialty products
Loramyc®/Oravig®
(oropharyngeal candidiasis in immunocompromised patients): Registered in
26 countries (EU, US, Korea)
Sitavir®/Sitavig®
(Acyclovir Lauriad®) (labialis herpes): Registered in 8
European countries, registration status in the US
Fentanyl Lauriad®
(chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin
Transdrug™) (primary liver cancer): Phase III on going
Validive®
(Clonidine Lauriad®) (mucositis): Phase II on going
AMEP®
(invasive melanoma): Phase I on going
For more information, visit
the BioAlliance Pharma web site at www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date
and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise.
For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of BioAlliance
Pharma SA to differ from those contained in the forward-looking
statements, please refer to the Risk Factors ("Facteurs de Risque")
section of the 2011 Reference Document filed with the AMF on April 24,
2012, which is available on the AMF website (http://www.amf-france.org)
or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
Source: BioAlliance Pharma